BAX vs BDX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and BDX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and BDX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

Becton, Dickinson and Company, known as BD, is one of the largest medical technology companies in the world, founded in 1897 and headquartered in Franklin Lakes, New Jersey. Most of what it sells is consumable rather than capital equipment: needles and syringes, IV catheters and vascular access sets, infusion pumps and their disposable sets, surgical and specimen-collection products, prefillable syringes sold to pharmaceutical companies, and interventional devices used in urology, peripheral vascular and surgery. That mix matters because consumables are consumed and reordered, so a large share of revenue recurs each year regardless of hospital capital budgets. Following the February 2026 separation, BD reports in four segments: Medical Essentials (~$1.68 billion in the June 2026 quarter), Interventional (~$1.41 billion), Connected Care (~$1.22 billion) and BioPharma Systems (~$0.67 billion).

Full BDX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• BDX drivers: A simpler, pure-play medtech after the Waters separation; BioPharma Systems and injectable drug delivery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For BDX, the most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAX if you believe its drivers more; BDX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and BDX guides.

BAX. Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

BDX. All figures are approximate and tied to the asOf date; check live numbers before acting on any of them. The wide gap between the trailing GAAP multiple (~30x) and the forward multiple (~13x to ~14x) is not a growth forecast, it is mostly an artifact of separation charges, intangible amortization and discontinued-operations accounting depressing reported GAAP earnings, which is why BD and most analysts discuss adjusted EPS. Trailing revenue comparisons across fiscal 2025 and fiscal 2026 are not like-for-like, because the Biosciences and Diagnostic Solutions business moved to discontinued operations after the February 2026 close.

Headline figures (approximate, July 2026): BAX shows revenue (ttm, continuing ops) ~$10.7B, q1 2026 sales ~$2.7B, q1 2026 adjusted eps ~$0.36, market cap ~$11.5B; BDX shows revenue (ttm, continuing operations) ~$20.8 billion, q3 fiscal 2026 revenue (quarter ended june 2026) ~$5.0 billion, up ~5.4% as reported and ~4.4% currency-neutral, q3 fiscal 2026 eps ~$1.64 GAAP diluted from continuing operations, ~$3.23 adjusted, fiscal 2026 guidance (adjusted diluted eps) ~$12.62 to ~$12.72, with low-single-digit-plus revenue growth.

BAX and BDX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and BDX exposure against your real portfolio. It is not an investment adviser.